Rhenman & Partners Asset Management Ab Exelixis, Inc. Transaction History

Rhenman & Partners Asset Management Ab

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 17, 2020	SELL	$15.15 - $18.89 $4.85 Million - $6.04 Million	-320,000 Closed	0 $0
Q3 2019 Oct 16, 2019	SELL	$17.68 - $22.65 $2.48 Million - $3.17 Million	-140,000 Reduced 30.43%	320,000 $5.66 Million
Q2 2019 Jul 22, 2019	BUY	$18.93 - $24.75 $567,900 - $742,500	30,000 Added 6.98%	460,000 $9.83 Million
Q1 2019 Apr 11, 2019	SELL	$19.6 - $24.76 $10.4 Million - $13.1 Million	-528,994 Reduced 55.16%	430,000 $10.2 Million
Q4 2018 Feb 05, 2019	SELL	$13.65 - $21.8 $4.13 Million - $6.59 Million	-302,420 Reduced 23.97%	958,994 $18.9 Million

Q3 2018 Oct 03, 2018	BUY	$15.87 - $22.4 $5.08 Million - $7.17 Million	320,200 Added 34.02%	1,261,414 $22.4 Million
Q2 2018 Jul 20, 2018	SELL	$18.56 - $22.45 $835,200 - $1.01 Million	-45,000 Reduced 4.56%	941,214 $20.3 Million
Q1 2018 Apr 11, 2018	BUY	$22.15 - $31.89 $5.09 Million - $7.33 Million	230,000 Added 30.41%	986,214 $21.8 Million
Q4 2017 Jan 19, 2018	SELL	$24.23 - $30.93 $7.12 Million - $9.09 Million	-293,786 Reduced 27.98%	756,214 $23 Million
Q3 2017 Oct 13, 2017	BUY	$23.35 - $29.24 $24.5 Million - $30.7 Million	1,050,000	1,050,000 $25.4 Million

460

246M

1.7M

1.02M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $7.11B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.